Evidence map›Paper›PMID 35008419›Full record

ArticleCancers2022

RhoGDI2-Mediated Rac1 Recruitment to Filamin A Enhances Rac1 Activity and Promotes Invasive Abilities of Gastric Cancer Cells.

Hyo-Jin Kim, Ki-Jun Ryu, Minju Kim, Taeyoung Kim, Seon-Hee Kim, Hyeontak Han, Hyemin Kim, Keun-Seok Hong, Chae Yeong Song, Yeonga Choi and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 16 citations in OpenAlex.

  1. Filamin C activates MAPK/ERK signaling to facilitate epithelial-mesenchymal transition in bladder cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Tumor suppressive effect of low-frequency repetitive transcranial magnetic stimulation on glioblastoma progression.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. The Dual Function of RhoGDI2 in Immunity and Cancer.International journal of molecular sciences · 2023
    Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Hyo-Jin KimDivision of Applied Life Science, Gyeongsang National University, Jinju 52828, Korea.
Ki-Jun RyuDivision of Applied Life Science, Gyeongsang National University, Jinju 52828, Korea.
Minju KimDivision of Applied Life Science, Gyeongsang National University, Jinju 52828, Korea.
Taeyoung KimDivision of Applied Life Science, Gyeongsang National University, Jinju 52828, Korea.
Seon-Hee KimDivision of Applied Life Science, Gyeongsang National University, Jinju 52828, Korea.
Hyeontak HanDivision of Applied Life Science, Gyeongsang National University, Jinju 52828, Korea.
Hyemin KimDivision of Applied Life Science, Gyeongsang National University, Jinju 52828, Korea.
Keun-Seok HongDivision of Applied Life Science, Gyeongsang National University, Jinju 52828, Korea.
Chae Yeong SongDivision of Applied Life Science, Gyeongsang National University, Jinju 52828, Korea.
Yeonga ChoiDivision of Applied Life Science, Gyeongsang National University, Jinju 52828, Korea.
Cheol HwangboDivision of Applied Life Science, Gyeongsang National University, Jinju 52828, Korea.ORCID 0000-0001-6505-3080
Kwang Dong KimDivision of Applied Life Science, Gyeongsang National University, Jinju 52828, Korea.ORCID 0000-0002-5199-3415
Jiyun YooDivision of Applied Life Science, Gyeongsang National University, Jinju 52828, Korea.
Gyeongsang National University · KR

Funding

National Research Foundation of Korea 2021R1A5A8029490
6 · The paper itself

Abstract

Rho GDP dissociation inhibitor 2 (RhoGDI2), a regulator of Rho family GTPase, has been known to promote tumor growth and malignant progression in gastric cancer. We previously showed that RhoGDI2 positively regulates Rac1 activity and Rac1 activation is critical for RhoGDI2-induced gastric cancer cell invasion. In this study, to identify the precise molecular mechanism by which RhoGDI2 activates Rac1 activity, we performed two-hybrid screenings using yeast and found that RhoGDI2 plays an important role in the interaction between Rac1, Filamin A and Rac1 activation in gastric cancer cells. Moreover, we found that Filamin A is required for Rac1 activation and the invasive ability of gastric cancer cells. Depletion of Filamin A expression markedly reduced Rac1 activity in RhoGDI2-expressing gastric cancer cells. The migration and invasion ability of RhoGDI2-expressing gastric cancer cells also substantially decreased when Filamin A expression was depleted. Furthermore, we found that Trio, a Rac1-specific guanine nucleotide exchange factor (GEF), is critical for Rac1 activation and the invasive ability of gastric cancer cells. Therefore, we conclude that RhoGDI2 increases Rac1 activity by recruiting Rac1 to Filamin A and enhancing the interaction between Rac1 and Trio, which is critical for the invasive ability of gastric cancer cells.

Indexed as

Filamin Agastric cancerinvasionRac1RhoGDI2Trio

Identifiers

PMID35008419
PMCPMC8750349
OpenAlexW4206152724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.